
10X GENOMICS INC-CLASS A
TXGNASDAQTrading Snapshot
- Day Range
- $58.09 β $59.34
- 52-Week Range
- $11.16 β $59.87
- Volume
- $4.30B
- Avg Volume
- $3.46B
- Shares Outstanding
- 127.0M
- Next Earnings
- Oct 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $643M
- Last Q Revenue
- $151M
- P/E Ratio
- β
- P/S Ratio
- 12.3x
- EPS (TTM)
- $-0.59
- Dividend Yield
- β
Why Investors Own TXG
- βHigh-growth profile β revenue up +48.5% YoY with expanding US Equity exposure.
- βHealthy economics β 48% gross margin and 24% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About 10X GENOMICS INC-CLASS A
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
10X GENOMICS INC-CLASS A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift TXG price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
10X GENOMICS INC-CLASS A announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.